Join
Live feed
·
PRReleasevia Quantisnow
MeiraGTx Holdings plc logo

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

ByQuantisnow·Wall Street's wire, on your screen.
MGTX· MeiraGTx Holdings plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MGTX (MeiraGTx Holdings plc) and more on Quantisnow.